Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from uncomplicated routine blood and urine screens to complex oncology and genomic testing.
Last trade$369.56
Day change-$2.905 (-0.78%)
Day range$368.70 – $377.06
Volume322,001
Market cap$30.24B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$30.24B
Price / earnings
30.12×
Price / book
3.42×
Price / sales
2.07×
EV / sales
2.46×
EV / EBITDA
15.26×
Profitability
Earnings per share
$12.36
Return on assets
5.31%
Return on equity
11.35%
Dividend yield
0.78%
Liquidity and leverage
Debt / equity
0.67×
Current ratio
1.41×
Quick ratio
1.22×
Cash ratio
0.09×
Cash flow
Price / cash flow
16.66×
Price / free cash flow
23.5×
Free cash flow
$1.29B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for LH, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$3.81B
$3.73B
$3.54B
$3.52B
$3.56B
$3.53B
$3.35B
$3.33B
Cost of revenue
$2.7B
$2.62B
$2.52B
$2.52B
$2.54B
$2.48B
$2.4B
$2.43B
Gross profit
$1.11B
$1.11B
$1.01B
$993.2M
$1.03B
$1.05B
$948M
$896.3M
Selling, general and administrative
$611.4M
$577.2M
$551M
$538.6M
$553.1M
$579.3M
$546M
$595.2M
Research and development
$0
$0
$0
$0
$0
$0
$0
$0
Total operating expenses
$706M
$660.4M
$633M
$725.6M
$628.5M
$651.7M
$622M
$679.8M
Operating income
$402.1M
$451.6M
$380.8M
$267.6M
$396.6M
$394.5M
$326M
$216.5M
Interest expense
-$59.1M
-$61.1M
-$55.1M
-$55M
-$56M
-$57.1M
-$56M
-$63.4M
Income before taxes
$328M
$386.4M
$319.7M
$190.6M
$337M
$304.7M
$275.2M
$183.8M
Income taxes
$64.9M
$87.3M
$41.7M
$25.7M
$75.5M
$66.4M
$62.2M
$40.2M
Net income
$263.1M
$299.1M
$278M
$164.9M
$261.5M
$238.3M
$213M
$143.6M
Net income attributable to common shareholders
$262.8M
$298.7M
$277.8M
$164.7M
$261.1M
$237.9M
$212.8M
$143.4M
EBITDA
$601M
$635.7M
$560.5M
$555M
$573.5M
$568.9M
$499.2M
$401.3M
Basic earnings per share
$3.24
$3.66
$3.37
$1.99
$3.14
$2.85
$2.54
$1.72
Diluted earnings per share
$3.22
$3.64
$3.35
$1.98
$3.12
$2.84
$2.52
$1.70
Recent news
Company coverage with links to the original publishers.
Labcorp reported 7% revenue growth to $3.8 billion in Q3 2026 with raised full-year guidance. The company faces a $125 million Medicare reimbursement headwind from proposed PAMA fee schedule changes in 2027, but plans to offset this through volume growth and cost efficiencies. Specialty testing is growing 3x faster than the broader diagnostics market, and tuck-in acquisitions from BioReference, Myriad Genetics' prenatal business, and Millennium Health are expected to be accretive to earnings in year one.
Labcorp Holdings (LH) has surged 48.2% year-to-date, driven by expansion in specialty testing markets, AI and automation initiatives, and six consecutive quarters of margin expansion. However, currency headwinds, intense competition, and acquisition-related execution risks could limit future growth. The company maintains a Zacks Rank #3 (Hold) with a 5% earnings yield.
Labcorp Holdings (LH), a leading healthcare diagnostics company, is highlighted as a stock to watch with a #3 (Hold) Zacks Rank and a VGM Score of B. The company has attractive valuation metrics with a forward P/E ratio of 20.01 and has seen six analyst upward earnings revisions in the last 60 days, with the Zacks Consensus Estimate increasing to $18.40 per share.
U.S. stock markets rose on Wednesday as the Federal Reserve kept interest rates unchanged at 3.75-4% and strong third-quarter earnings boosted investor confidence. The Dow Jones, Nasdaq Composite, and S&P 500 all ended in positive territory. Notable earnings beats from Seagate Technology, Amphenol Corp., and Labcorp Holdings drove their stock prices higher by 4.5%, 3.5%, and 8.8% respectively.
Labcorp Holdings (LH) reported Q3 2026 adjusted EPS of $4.78, up 14.5% year-over-year, and revenues of $3.81 billion, up 6.9%, both beating consensus estimates. The company raised its full-year 2026 revenue guidance to 5.9-6.7% and adjusted EPS guidance to $18.30-$18.70, driven by strong organic growth across both Diagnostics and Biopharma Laboratory Services segments and margin expansion.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
Declared upcoming dividend$0.72 per share
Declared
Oct 20, 2026
Ex-dividend
Nov 24, 2026
Pay date
Dec 11, 2026
Ex-dividend
Amount / share
Pay date
Type
Aug 28, 2026
$0.72
Sep 11, 2026
recurring
May 29, 2026
$0.72
Jun 11, 2026
recurring
Feb 27, 2026
$0.72
Mar 12, 2026
recurring
Nov 26, 2025
$0.72
Dec 11, 2025
recurring
Aug 28, 2025
$0.72
Sep 11, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.